MEDTECH - Jean Boulle Group
Related articles on the Tendyne valve:
ABOUT JEAN BOULLE MEDTECH’S TRADEMARKED LOGO:
If you look closely at the geometric heart in the logo you will see a diamond-shaped octahedron overlay which repeats to create the “flower of life” symbol. The logo combines the elements of diamonds (the Jean Boulle Group’s first initiative), the heart and the tri-leaflet pattern from its first life-saving medical technology project (Tendyne), and the flower of life (symbolizing the focus of Jean Boulle Medtech – saving and improving the quality of people’s lives).
TENDYNE HOLDINGS INC.
Jean Boulle Medtech’s most recent success is Tendyne Holdings, Inc., which has developed one of the most promising Transcatheter mitral valve implant (“TMVI”) devices in existence today. The Tendyne TMVI is a fully-retrievable and repositionable, apically-tethered tri-leaflet porcine pericardial valve sewn onto a Nitinol (nickel/titanium composite) frame specifically designed to address the complex mitral anatomy of functional, degenerative and mixed etiology mitral regurgitation. Left untreated, mitral regurgitation can lead to heart failure and death. Implanted in a beating heart, the Tendyne valve has proprietary and patented features that permit a significantly less invasive procedure to mitral valve treatment than open heart surgery. This life- saving device currently is in worldwide clinical trials in the United States, the United Kingdom, and Australia at renowned hospitals such as Baylor’s Hamilton Heart and Vascular Hospital in Dallas, Texas; the Minneapolis Heart Institute and Abbott Northwestern Hospital in Minneapolis Minnesota; the Royal Brompton Hospital in London, England; and St. Vincent’s Hospital, Sydney Australia, among others. Tendyne and the hospitals are reporting positive outcomes. Jean Boulle Medtech was the founding investor of Tendyne and helped guide the company through its many stages of development. In 2012 and 2014 respectively, Jean Boulle Medtech welcomed Abbott Laboratories and Apple Tree Partners as Tendyne’s other major investors. Tendyne was acquired by Abbott in September 2015.
For more information, see www.tendyne.com
Jean Boulle Medtech currently is establishing, investing in and reviewing several companies and projects, among them companies and projects relating to the treatment of age-related macular degeneration and the development of implantable venus valves. Confidentiality and protection of proprietary technologies limit the information that can be provided at this time but more information will be made available as circumstances permit.
Jean Boulle Medtech welcomes inquires from those seeking financial and technical expertise to develop technologies that saves lives or improves the quality of life.